Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

Background Knowledge regarding differences in care for psoriatic patients is limited. The aim of this study was to investigate factors influencing prescription of systemic treatments for patients with psoriasis with a special focus on socioeconomic factors. Methods and findings This was a non-interventional, cross-sectional study, conducted in 18 Italian University and/or hospital centers with psoriasis-specialized units. Questionnaires evaluating demographic and socioeconomic characteristics were administered to participants. Overall, 1880 consecutive patients affected by mild-to-severe psoriasis were recruited. Univariate and multivariable logistic regression analyses of systemic therapy prescription, with a special focus on biologics, accounting for the above mentioned characteristics were performed. Our analysis showed that all analyzed patients’ characteristics were significantly associated with biological therapy compared to non-biological systemic one. Particularly, women were less likely to receive biologics than men (OR = 0.66; 95% CI, 0.57–0.77). Elderly patients (≥65 years) and subjects with a BMI ≥30 had lower odds to receive biologics respect to adults (≥35–64 years) (OR = 0.33; 95% CI, 0.25–0.40), and subjects with BMI≥25<30 (OR = 0.64; 95% CI, 0.53–0.77), respectively. Northern and Southern patients were both less likely to receive biologics than Central patients (OR = 0.75; 95% CI, 0.63–0.89, and OR = 0.56; 95% CI,0.47–0.68, respectively). Lower economic profile and never reading books were both associated with decreased odds of receiving biological therapy. Conclusions This study shows that sex, age, comorbidities, and socioeconomic characteristics influence the prescription of systemic treatments in psoriasis, highlighting that there are still unmet needs influencing the therapeutic decision-making process that have to be addressed.

[1]  A. Balato,et al.  Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study , 2019, American Journal of Clinical Dermatology.

[2]  G. Fabbrocini,et al.  Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1‐year period , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  S. Feldman,et al.  Treatment decisions in psoriasis. , 2019, Journal of comparative effectiveness research.

[4]  L. Atzori,et al.  Biologics exposure during pregnancy and breastfeeding in a psoriasis patient , 2019, Dermatologic therapy.

[5]  G. Varigos,et al.  Baseline patients’ characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments , 2018, The Australasian journal of dermatology.

[6]  G. Fabbrocini,et al.  Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows , 2018, Front. Immunol..

[7]  M. Romanelli,et al.  Elderly psoriatic patients under biological therapies: an Italian experience , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  M. Megna,et al.  Real‐life effectiveness of biological drugs on psoriatic difficult‐to‐treat body regions: scalp, palmoplantar area and lower limbs , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  K. Payne,et al.  Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength , 2017, The Journal of investigative dermatology.

[10]  Shuai Xu,et al.  Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed , 2017, Journal of the American Academy of Dermatology.

[11]  N. Balato,et al.  Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders , 2017, Expert opinion on biological therapy.

[12]  L. Naldi,et al.  Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  L. Naldi,et al.  Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry , 2017, The British journal of dermatology.

[14]  M. Megna,et al.  Soccer helps in controlling the development of psoriasis in Italian second league players , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  Nilendu Sarma Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis , 2017, Indian journal of dermatology.

[16]  A. Kimball,et al.  Update on biologic safety for patients with psoriasis during pregnancy , 2017, International journal of women's dermatology.

[17]  R. Althin,et al.  Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients , 2017, BioDrugs.

[18]  M. Megna,et al.  Psoriasis in elderly and non-elderly population: clinical and molecular features. , 2016, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[19]  M. Megna,et al.  Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2‐year period , 2016, Clinical and experimental dermatology.

[20]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[21]  M. Megna,et al.  Psoriasis and sport: a new ally? , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  Z. Adamski,et al.  Factors affecting response to biologic treatment in psoriasis , 2014, Dermatologic therapy.

[23]  J. Schmitt,et al.  A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  D. Terris,et al.  Matching physicians’ treatment recommendations to patients’ treatment preferences is associated with improvement in treatment satisfaction , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  M. Eriksson,et al.  The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men , 2013, PloS one.

[26]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[27]  Nasir Umar,et al.  Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology , 2012, BMC Health Services Research.

[28]  A. Menter,et al.  Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. , 2010, Journal of the American Academy of Dermatology.

[29]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[30]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[31]  B. Evengård,et al.  “The Laundry Bag Project”– unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden , 2008, International journal of dermatology.

[32]  F. Taroni,et al.  The Italian health-care system. , 2005, Health economics.

[33]  E. Chung,et al.  Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.

[34]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[35]  K. Kragballe,et al.  Experience of Being Young With Psoriasis: Self-Management Support Needs , 2018, Qualitative health research.

[36]  E. Edson-Heredia,et al.  Heterogeneity of response to biologic treatment: perspective for psoriasis. , 2014, The Journal of investigative dermatology.